Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Rhea-AI Summary

Silverback Therapeutics, Inc. (Nasdaq: SBTX) reported its third quarter financial results for the period ending September 30, 2021. The company incurred a net loss of $22.7 million, up from $8.1 million in the same period last year. R&D expenses surged to $15.6 million compared to $6.2 million in Q3 2020, reflecting increased clinical development efforts. Silverback also highlighted progress in its pipeline, including SBT6050's Phase 1/1b study and the upcoming initiation of SBT6290 and SBT8230 trials, with cash reserves at $340.6 million to fund operations through 2024.

Positive

• SBT6050 shows proof-of-mechanism with early anti-tumor activity signals.
• SBT6290 Investigational New Drug application submitted to the FDA.
• Strong cash position of $340.6 million to fund operations into 2024.

Negative

• Net loss increased significantly to $22.7 million from $8.1 million year-over-year.
• R&D expenses more than doubled compared to Q3 2020, reaching $15.6 million.
• General and administrative expenses rose sharply to $7.0 million, compared to $1.9 million in the prior year.

SEATTLE--(BUSINESS WIRE)-- Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results for the third quarter ended September 30, 2021, and provided a business update.

“In the third quarter, we provided our first interim clinical update for the dose escalation arms of the SBT6050-101 trial, establishing proof-of-mechanism for SBT6050 as evidenced by the activation of the innate and adaptive immune system in patients,” said Laura Shawver, Ph.D., chief executive officer of Silverback. “In a short period of time, we have accumulated a robust clinical data set that has informed our development strategy. We are focused on advancing SBT6050 in patients with HER2-expressing cancers such as gastroesophageal and non-small cell lung, in combination with agents that we believe will maximize the therapeutic potential of our first-in-class TLR8 agonist conjugate. We also look forward to continuing to advance our pipeline, including SBT6290 for patients with bladder, triple negative breast, non-small cell lung, and head & neck cancers, and SBT8230 for patients with chronic hepatitis B virus.”

Recent Business Updates:

SBT6050 (HER2-TL8 ImmunoTAC)

• Interim clinical data presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting. In September 2021, Silverback presented interim clinical results from the ongoing Phase 1/1b study of SBT6050, including data that establish proof-of-mechanism through SBT6050’s ability to activate myeloid, T and NK cells, as well as evidence of SBT6050 payload localization in the tumor microenvironment. Adverse events reported were consistent with on-mechanism immune activation, and early signals of anti-tumor activity were observed.
• Selected go forward dose of 0.3 mg/kg SBT6050 in combination with anti-PD-1 therapy in expansion cohorts. Silverback is prioritizing combination with Libtayo in gastroesophageal and non-small cell lung cancers and plans to initiate these expansion cohorts in the fourth quarter of 2021.
• SBT6050 expanded clinical development strategy announced, leveraging combination with trastuzumab-containing regimens. In the first quarter of 2022, Silverback plans to initiate SBT6050-201, a Phase 1/2 study of SBT6050 combined with Enhertu, or with Herceptin and Tukysa with or without capecitabine, in patients with HER2-expressing or HER2-amplified cancers.

SBT6290 (Nectin4-TL8 ImmunoTAC)

• SBT6290 Investigational New Drug application submitted to the U.S. Food and Drug Administration. Silverback remains on track to initiate the phase 1/1b trial in the first quarter of 2022, and plans to enroll patients with bladder, non-small cell lung, triple negative breast, and head and neck cancers in dose escalation.

SBT8230 (ASGR1-TLR8 ImmunoTAC for chronic HBV)

• SBT8230 preclinical development continues with GLP toxicology studies expected to commence in the first quarter of 2022. Silverback will be providing a preclinical update on the SBT8230 program at the American Association for the Study of Liver Diseases (AASLD) 2021 conference held from November 12-14, 2021.

Third Quarter Financial Results

For the third quarter ended September 30, 2021, Silverback reported a net loss of $22.7 million, compared to a net loss of $8.1 million for the comparable period in 2020. For the nine months ended September 30, 2021, Silverback reported a net loss of $66.0 million, compared to a net loss of $19.9 million for the comparable period in 2020. Included in the net losses for the three and nine months ended September 30, 2021 were $5.0 million and $14.0 million of non-cash stock-based compensation, respectively, compared to $0.2 million and $0.4 million for the same periods in 2020, respectively.

Research and development expenses for the third quarter ended September 30, 2021 were $15.6 million, compared to $6.2 million for the same period in 2020. Research and development expenses for the nine months ended September 30, 2021 were $45.6 million compared to $15.7 million for the same period in 2020. The increases in the Company’s research and development expenses in 2021 were primarily attributable to the advancement of pipeline programs, including SBT6290 and SBT8230, through preclinical development and the continued clinical development of SBT6050. Silverback also incurred additional personnel-related expenses as operations grew in support of program advancements.

General and administrative expenses for the third quarter ended September 30, 2021 were $7.0 million, compared to $1.9 million for the same period in 2020. General and administrative expenses for the nine months ended September 30, 2021 were $20.4 million, compared to $4.1 million for the same period in 2020. The increases in general and administrative expenses were primarily attributable to an increase in personnel-related expenses due to increased headcount in 2021, including new executives, as well as increases in salaries, bonuses, and stock-based compensation. The increases in general and administrative expenses were also due to an increase in legal fees, professional fees, and other various general and administrative expenses as we now operate as a public company.

As of September 30, 2021, Silverback reported cash, cash equivalents, and investments of $340.6 million compared to cash and cash equivalents of $386.6 million at December 31, 2020, which is expected to fund operating expenses and capital expenditure requirements into 2024.

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Silverback’s plans and ability to bring new treatments to patients in need, including potential combination efforts, the progress and expected timing of Silverback’s drug development programs and clinical trials, and the strength of Silverback’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Silverback may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties that Silverback faces, please refer to Silverback’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Silverback assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Silverback Therapeutics, Inc.
Condensed Balance Sheets
(in thousands, except share and par value data)
			September 30,				December 31,
			2021				2020
			(unaudited)
Assets
Current assets:
Cash and cash equivalents			$	300,660			$	386,569
Prepaid expenses and other current assets				4,695				4,087
Total current assets				305,355				390,656
Investments				39,938				—
Restricted cash				350				350
Right-of-use asset				5,011				2,180
Property and equipment, net				1,907				1,618
Total assets			$	352,561			$	394,804
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable			$	1,720			$	2,583
Accrued expenses				12,537				5,278
Term loan payable, net				—				844
Current portion of lease liability				1,090				896
Total current liabilities				15,347				9,601
Lease liability, net of current portion				5,080				2,326
Total liabilities				20,427				11,927
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020				—				—
Common stock, $0.0001 par value per share; 200,000,000 shares authorized at September 30, 2021 and December 31, 2020, 35,067,751 and 34,801,537 shares issued and 35,037,136 and 34,701,274 shares outstanding at September 30, 2021 and December 31, 2020, respectively				4				3
Additional paid-in capital				494,916				479,608
Accumulated other comprehensive loss				(34	)			—
Accumulated deficit				(162,752	)			(96,734	)
Total stockholders’ equity				332,134				382,877
Total liabilities, and stockholders’ equity			$	352,561			$	394,804

Silverback Therapeutics, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2021				2020				2021				2020
Operating expenses:
Research and development		$	15,641			$	6,200				45,630			$	15,740
General and administrative			7,040				1,912				20,447				4,077
Total operating expenses			22,681				8,112				66,077				19,817
Loss from operations			(22,681	)			(8,112	)			(66,077	)			(19,817	)
Interest income (expense), net			26				(4	)			59				(45	)
Net loss		$	(22,655	)		$	(8,116	)			(66,018	)		$	(19,862	)
Unrealized gain (loss) on available-for-sale securities			(34	)			—				(34	)			—
Comprehensive loss attributable to common stockholders		$	(22,689	)		$	(8,116	)			(66,052	)		$	(19,862	)
Net loss per share applicable to common stockholders, basic and diluted		$	(0.65	)		$	(11.97	)		$	(1.89	)		$	(29.53	)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted			35,001,466				678,048				34,884,656				672,531

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005340/en/

Investor Contact:

Miguel Arcinas

Silverback Therapeutics

(206) 736-7946

ir@silverbacktx.com

Media Contact:

Jason Spark

Canale Communications

(619) 849-6005

jason.spark@canalecomm.com

Source: Silverback Therapeutics, Inc.

FAQ

What were Silverback Therapeutics' third quarter financial results for 2021?

Silverback reported a net loss of $22.7 million for Q3 2021, compared to $8.1 million in Q3 2020.

What is the cash position of Silverback Therapeutics as of September 30, 2021?

As of September 30, 2021, Silverback reported cash, cash equivalents, and investments of $340.6 million.

What are the upcoming clinical trials for Silverback Therapeutics?

Silverback plans to initiate trials for SBT6290 and SBT8230 in early 2022.

How did Silverback's research and development expenses change in Q3 2021?

R&D expenses rose to $15.6 million in Q3 2021, significantly higher than $6.2 million in Q3 2020.